One of the most well-documented examples is the emergence of secondary mutations in the BCR-ABL fusion protein in chronic myeloid leukemia (CML), which confers resistance to tyrosine kinase inhibitors (TKIs) such as imatinib. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.